bit.bio further expands ioCells™️ range with early access launch of ioMotor Neurons™️ for research and drug discovery in diseases such as amyotrophic lateral sclerosis (ALS)
This takes the total number of products in the ioCells range - human cells for research and drug discovery - to 20 products, including wild type, CRISPR-ready and disease model cells.
- This takes the total number of products in the ioCells range - human cells for research and drug discovery - to 20 products, including wild type, CRISPR-ready and disease model cells.
- The launch of ioMotor Neurons also follows the recent opening of bit.bio’s new manufacturing and automation laboratories by the UK’s Minister for Science, Research and Innovation.
- Damage or death of motor neurons can lead to a devastating group of conditions called Motor Neuron Diseases (MNDs).
- ioMotor Neurons are an important part of our ALS toolkit that can now be incorporated into motor neuron disease research and early drug discovery workflows in ways that were not previously possible.